The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling

Brijal M. Desai1,9, Jessie Villanueva19, Thierry-Thien K. Nguyen1, Mercedes Lioni1, Min Xiao1, Jun Kong1, Clemens Krepler1, Adina Vultur1, Keith T. Flaherty2, Katherine L. Nathanson3, Keiran S. M. Smalley4, Meenhard Herlyn1*

1 The Wistar Institute, Philadelphia, Pennsylvania, United States of America, 2 Massachusetts General Hospital, Boston, Massachusetts, United States of America, 3 Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America, 4 Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America

Abstract

Although cyclin dependent kinase (CDK)-2 is known to be dispensable for the growth of most tumors, it is thought to be important for the proliferation of melanoma cells, where its expression is controlled by the melanocyte-lineage specific transcription factor MITF. Treatment of a panel of melanoma cells with the CDK inhibitor dinaciclib led to a concentration-dependent inhibition of growth under both 2D adherent and 3D organotypic cell culture conditions. Dinaciclib targeted melanoma cell lines regardless of cdk2 or MITF levels. Inhibition of growth was associated with a rapid induction of G2/M cell arrest and apoptosis. Treatment of human melanoma mouse xenografts with dinaciclib led to tumor regression associated with reduced retinoblastoma protein phosphorylation and Bcl-2 expression. Further mechanistic studies revealed that dinaciclib induces p53 expression whilst simultaneously downregulating the expression of the anti-apoptotic factors Mcl-1 and XIAP. To clarify the role of p53 activation in the dinaciclib-induced cell death, we generated melanoma cell lines in which p53 expression was knocked down using a shRNA lentiviral vector. Knockdown of p53 completely abolished the induction of apoptosis seen following dinaciclib treatment as shown by a lack of annexin-V staining and caspase-3 cleavage. Altogether, these data show that dinaciclib induces apoptosis in a large panel of melanoma cell lines through a mechanism requiring p53 expression.

Introduction

The landscape of melanoma therapy has changed dramatically within the last few years with the discovery that the majority of melanomas harbor activating mutations in \textit{BRAF} [1,2] and that virtually all melanomas exhibit constitutive activity in the MAP kinase pathway [3]. Recently, two novel drugs were approved for the treatment of metastatic melanoma and several more are in late stage clinical development [4]. In the class of small molecule kinase inhibitors, the \textit{BRAF} inhibitor vemurafenib has shown unprecedented clinical activity; but unfortunately, patients eventually develop resistance [5]. The mechanisms leading to this are under intense scrutiny and as shown by recent publications, melanoma cells can escape by various means [4,6,7,8,9]. The field is thus increasingly accepting the notion that novel targets outside of the MAPK pathway will be necessary to avoid emergence of resistant subpopulations and that combinations of inhibitors are the most likely to provide long lasting results [10]. Increased efforts are thus now focused on finding agents that are able to induce melanoma cell death and that may be advantageous in combination therapies with inhibitors of the MAPK pathway. Additionally, there are 50\% of melanoma patients whose tumors do not harbor \textit{BRAF} mutations and for whom no effective therapies are currently available.

One intriguing aspect of melanoma cells is that although they generally lack p53 mutations, they are poor at undergoing p53-dependent apoptosis [11]. Recent studies have demonstrated that p53 transcriptional targets are aberrantly expressed in melanoma; therefore reactivation of p53 could restore the proliferative balance and resistance to apoptosis in melanoma ([12]. In fact, pre-clinical studies from our laboratory and others have indicated that p53 can be activated in melanoma cell lines, leading to the induction of apoptosis; thus the p53-dependent signaling system is not entirely dysfunctional [13,14]. One family of compounds that could induce p53-dependent apoptosis are the cyclin dependent
Figure 1. Expression of CDK2 and MITF in a panel of melanoma cell lines. A) CDK2 mRNA and protein expression levels in a panel of melanoma cell lines. mRNA levels in the melanoma panel were measured via microarray analysis. Data shows melanoma cell lines harboring the BRAF V600E mutation (blue) and the NRAS mutations (red). Protein expression was measured by Western blotting. B) MITF mRNA and protein expression...
levels in a panel of melanoma cell lines. mRNA levels in the melanoma cell lines were measured via microarray analysis. Data shows melanoma cell lines harboring the \textit{BRAF} V600E mutation (blue) and the \textit{NRAS} mutations (red). MITF protein expression was measured by Western blotting. Blots were stripped once and probed for actin to show equal protein loading. Relative CDK2 expression is denoted as “CDK2 LOW” and “CDK2 HIGH”.

doi:10.1371/journal.pone.0059588.g001

kinase (CDK) inhibitors [15]. CDKs are a family of serine threonine kinases that regulate both cell cycle progression and transcription through the phosphorylation of RNA polymerase II [15,16,17].

Cancer cells often have deregulated cell cycle regulatory mechanisms. One of the most critical steps in cell cycle entry is the phosphorylation and inactivation of the retinoblastoma (RB) protein by CDK4/6 and CDK2 [16], leading to the dissociation of the RB protein and the E2F family of transcription factors. Increased E2F activity induces transcription of E2F-dependent genes such as cyclin A, dihydrofolate reductase, thymidine kinase, and DNA polymerase-\(\alpha\), and promotes S-phase [19,20,21]. A second group of CDKs do not regulate the cell cycle but rather control RNA stability and transcription. This second family of CDKs include complexes such as cyclin H-CDK7, which phosphorylates the carboxy terminal domain of RNA polymerase II, and cyclin T-CDK9, which promote the initiation and elongation of RNA transcripts [22,23]. Pre-clinical studies have shown that inhibition of CDK9, using flavopiridol, can reduce the expression of short-lived RNA transcripts that encode for anti-apoptotic proteins leading to cell death [15].

Among the CDK family, CDK2 has a unique role in the development and progression of melanoma. A recent study showed that CDK2 expression was regulated in melanoma cells by the melanocyte specific transcription factor MITF [24], and that CDK2 knockdown significantly reduced melanoma growth. It was further demonstrated that melanoma cell lines with lower expression of CDK2 were more sensitive to the cyclin-dependent inhibitor roscovitine [24]. These studies led to the hypothesis that CDK2 could be a useful melanoma therapeutic target.

In the present study, we have evaluated the anti-melanoma activity of a CDK1/2/5/9 inhibitor, dinaciclib, and demonstrated that the compound has broad-spectrum anti-proliferative and p53-dependent pro-apoptotic activity against a panel of melanoma cell lines.

Materials and Methods

Ethics Statement

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Wistar Institute Animal Care and Use Committee (Protocol Number: 111954). All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize animal suffering.

Cell Culture

Melanoma cells were cultured as described in [25]. The lentiviral vector short hairpin RNA (shRNA) constructs for p53 were developed in the laboratory of Dr. Maria Soengas, based on published sequences [13,26]. Pools of p53-shRNA transduced cells were utilized in this study.

Expression/mutational Profiling

Melanoma samples were prepared for analysis on the Affymetrix U133A array platform [27]. Cell lines represented in Fig. 1A and B are (in order): WM35, WM278, 1205Lu, WM88, WM983A, WM983B, WM1617, WM1799, WM1346, WM1361A, and WM1366. The data generated from these arrays has been published previously [27,28] and have been deposited in the National Center for Biotechnology Information’s Gene Expression Omnibus website (http://www.ncbi.nlm.nih.gov/geo/). Data are accessible using Gene Expression Omnibus Series accession GSE4845. Mutational profiling of \textit{BRAF} (Exon 15) and \textit{NRAS} (Exon 3) was performed by PCR as previously described [29].

Adherent Cell Proliferation Assay

Cells were plated into a 96-well plate at a density of 2.5\times10^4 cells per mL and left to grow overnight. Cells were treated with increasing concentrations of dinaciclib in triplicate. In each experiment, cells were grown for 72 hrs treated with 20 \(\mu\)L 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma, St Louis, MO) reagent for 3 h. After this time, medium was rapidly removed and the resulting crystals were solubilized in DMSO. Absorbance was read in a plate reader at 540 nm. Absorbance readings were subtracted from the value of blank wells, and the reduction in cell growth was calculated as a percentage of control absorbance in the absence of any drug. Data show the mean of at least three independent experiments \pm SE mean.

Western Blot Analysis

Proteins were extracted and blotted as described in [25]. After analysis, Western blots were stripped once and re-probed for \(\beta\)-actin to show even protein loading. Antibodies for pRB ser807/811, caspase-3, Bcl-2, XIAP, and Mcl-1 were from Cell Signaling Technology (Beverly, MA). The monoclonal antibody to \(\beta\)-actin was from Sigma, the monoclonal antibody for CDK2 was from Calbiochem (Darmstadt, Germany).

Three-dimensional Spheroid Growth Assay

Melanoma spheroids were prepared using the liquid overlay method and treated as described previously [30]. Spheroids were treated with either 10 nM or 30 nM of dinaciclib for 72 hrs, prior to being stained using a LIVE/DEAD cell viability kit (Invitrogen, Carlsbad, Ca.).

Cell Cycle Analysis

Cells were plated into 10 cm dishes at 60% confluency and left to grow overnight before treatment with 30 nM of dinaciclib for 12 or 24 hours. Cells were then treated and analyzed as described previously [13]. Briefly, melanoma cells were fixed in 70% ethanol and stained with propidium iodide (5 mg/mL Sigma Aldrich).

Flow Cytometric Analysis of Apoptosis

After treatment of the cells with 30 nM dinaciclib for 48 hr, cells were washed once with Annexin V phosphatase buffer [10 mmol/L HEPES (pH 7.4), 140 mmol/L NaCl, 5 mmol/L CaCl\(_2\)], resuspended in 100 \(\mu\)L binding buffer containing 3 \(\mu\)L FITC-conjugated Annexin V (R&D Systems, Minneapolis, MN) and 1 \(\mu\)L Propidium Iodide (5 mg/mL Sigma Aldrich).
Figure 2. Dinaciclib inhibits the growth and survival of melanoma cell lines grown under both 2D adherent culture and 3D organotypic cell culture conditions. A) Growth inhibition for melanoma cells treated with dinaciclib measured by the MTT assay. Cells were treated with increasing concentrations of dinaciclib (1 nM–10 μM) for 72 hours before treatment with the MTT reagent. Absorbances were read at 570 nm and expressed as a percentage of control. B) Dinaciclib reduces the viability and invasion of melanoma cells grown as three-dimensional collagen-implanted spheroids. Preformed melanoma spheroids that harbored either the BRAF V600E mutation (1205Lu) or NRAS mutation (WM1366) were embedded into collagen and overlaid with medium. Cells were then treated with either 10 nM or 30 nM dinaciclib for 72 hours before being stained with calcein-AM and ethidium bromide. Spheroids were visualized and photographed using an inverted fluorescence microscope. Green, viable cells; red, dead cells.

doi:10.1371/journal.pone.0059588.g002
The Anti-Melanoma Activity of Dinaciclib

A) 1205Lu

|          | UNTREATED | 12 hr | 24 hr |
|----------|-----------|-------|-------|
| Sub G1   | 1.14      | 3.55  | 11.33 |
| G0/G1:   | 63.26     | 41.69 | 41.44 |
| S:       | 15.64     | 15.63 | 9.32  |
| G2/M:    | 20.45     | 39.55 | 38.27 |

WM1366

|          | UNTREATED | 12 hr | 24 hr |
|----------|-----------|-------|-------|
| Sub G1   | 1.68      | 4.20  | 5.03  |
| G0/G1:   | 44.19     | 40.56 | 42.32 |
| S:       | 23.94     | 15.26 | 5.41  |
| G2/M:    | 30.79     | 40.38 | 44.52 |

B) Melanoma Panel: Apoptosis

|          | % Annexin V+ |
|----------|--------------|
| WM1799   |              |
| WM1617   |              |
| WM983B   |              |
| WM983A   |              |
| WM88     |              |
| WM278    |              |
| WM35     |              |
| WM1366   |              |
| WM1346   |              |
| WM1361A  |              |

CDK2 HIGH  CDK2 LOW
In vivo Melanoma Xenograft Studies

Each treatment group consisted of five severe combined immunodeficient (SCID) CB-17 mice (Charles River Laboratories). Ten mice were injected subcutaneously (s.c.) with WM1366 cells (2 × 10⁵) in Matrigel into the lower flank. Once animals developed melanoma nodules of ~5 mm in diameter, drug administration was initiated (day 1). SCID mice were randomly assigned to two experimental groups of five animals each: (a) 200 µL vehicle (20% hydroxypropyl β-cyclodextrin, HPBCD, Cargill Foods), and (b) 5 mg/kg dinaciclib in 200 µL HPBCD, three times per week intraperitoneally over a period of 14 days. Tumors were measured twice a week using digital calipers. Tumor volume was calculated as a product of three dimensions. Tumor shrinkage was calculated as a fold change relative to the starting volume. At treatment day 14, 1 h after the final drug application, all animals were euthanized.

Statistical Analysis

Unless otherwise stated, all experiments show the mean ± SE mean of at least three independent experiments. Statistical significance was measured using Student's t test, in which P<0.05 was judged to be significant.

Results

Dinaciclib Inhibits Melanoma Growth Independently of CDK2 Expression Levels and BRAF/NRAS Mutational Status in 2D and 3D Melanoma Models

It has been previously shown that MITF is critical for maintaining the expression of CDK2 in melanoma cells, and that that levels of both CDK2 and MITF predict responses to the CDK inhibitor roscovitine [24]. In an initial series of studies, we examined the relationship between CDK2/MITF mRNA and protein expression levels and response to treatment by dinaciclib. After screening a large panel of melanoma cell lines, we identified 5 melanoma cell lines that expressed high levels of CDK2 mRNA (CDK2 HIGH) and 6 that expressed low levels of CDK2 mRNA (CDK2 LOW) (Figure 1). As BRAF/NRAS mutational status is also thought to predict targeted therapy response in melanoma, we further sub-stratified the groups according to CDK2 melanoma cell lines that harbored mutations in either BRAF V600E or NRAS. The RNA levels of CDK2 correlated well with levels of CDK2 protein expression. In contrast, RNA levels of MITF were not found to clearly correlate with protein expression (Figure 1A–B).

Treatment of melanoma cells with increasing concentrations of dinaciclib for 72 h led to a concentration dependent inhibition of cell growth (Figure 2A). Interestingly, there was no selectivity in the extent of growth inhibition observed across the cell lines with either high/low CDK2 expression levels or the presence of a BRAF/NRAS mutation.

Previous studies from our group have shown that growth of melanoma cell lines as 3D collagen-implanted spheroids increases their drug resistance [30]. Here, we found that treatment of either the BRAF V600E mutated 1205Lu cell line or the NRAS mutated WM1366 cell line with dinaciclib for 72 hrs led to a marked loss of cell viability, as shown by the loss of green staining and increase in red staining, and lack of invasion into the surrounding collagen. The mean length of invasion was reduced from 160 µm in the control 1205Lu spheroids to 106 and 25 µm following treatment with dinaciclib at 10 nM or 30 nM respectively. Similarly, WM1366 spheroids treated with DMSO or dinaciclib at 10 nM or 30 nM displayed a length of invasion of 31, 5, and 3 µm respectively (Table S1).

Dinaciclib Treatment is Associated with G2/M Phase Cell Cycle Arrest and the Induction of Apoptosis

To examine the effect of dinaciclib on cell cycle progression, a BRAF V600E mutated cell line (1205Lu) and NRAS mutated cell line (WM1366) were incubated with 30 nM of drug for increasing periods of time (Figure 3A). Treatment of both cell lines with dinaciclib induced a G2/M phase cell cycle arrest associated with the loss of cells progressing through S-phase and an increase in the number of cells accumulating in the sub-G1 fraction of the cell cycle (Figure 3A). To further investigate the potential pro-apoptotic effects of dinaciclib and to examine if these effects were related to NRAS/BRAF mutational status or CDK2 expression levels, we treated the entire panel of cell lines with dinaciclib (30 nM) for 24 hrs (Figure 3B). Dinaciclib induced apoptosis in all cell lines tested, with effects ranging from 19% (WM1361A) to 65% (WM88) of Annexin V-positive cells (Figure 3B). The ability of dinaciclib to induce apoptosis in the melanoma cell line panel was unrelated to either CDK2 expression levels or BRAF/NRAS mutational status, suggesting that this drug had broad-spectrum anti-melanoma activity.

Dinaciclib Causes Tumor Regression in a Mouse Xenograft Melanoma Model

We next examined whether the observed anti-melanoma effects of dinaciclib in vitro monolayer cultures and 3D organotypic models translated into the in vivo setting. As all of the melanoma lines tested responded to treatment in a similar manner in the in vitro assays, we chose to perform the mouse xenograft experiments with the WM1366 cell line (CDK2 low/NRAS mutated) to assess if the compound would still be effective if CDK2 levels were low. Furthermore, we were interested in determining if dinaciclib could have therapeutic efficacy in an NRAS mutant melanoma, as there are currently no effective therapies for these types of tumors. After tumor establishment (5 × 5 mm), SCID mice were dosed three times per week with 5 mg/kg dinaciclib by intraperitoneal injection. After 14 days, we observed that dinaciclib treatment significantly suppressed tumor growth, leading to regression of the original lesion (Figure 4A–B). Indeed, the tumor was barely visible following a two-week dinaciclib treatment (Figure 4A). To assess the biochemical effects of dinaciclib in vivo, tumors were harvested from both groups of mice at day 14 and were analyzed for markers of anti-CDK activity. Treatment of mice with dinaciclib was found to reduce RB phosphorylation at Ser807/811 (Figure 4C), indicative of CDK2 inhibition. We hypothesize that the dinaciclib pro-apoptotic effect was likely mediated by the inhibition of transcriptional CDKs such as CDK7 and CDK9, which regulate the expression of anti-apoptotic proteins such as Bcl-2 and Mcl-1.
In line with this hypothesis, we found a decrease in Bcl-2 expression in the dinaciclib treated tumors and an increase in p53 expression (Figure 4C). Sequencing of p53 in the WM1366 cell line indicated a p53 E285K missense mutation in the transactivation domain. This mutant has a nearly identical transactivation activity compared to wild type p53 [31].

Figure 4. Dinaciclib induces regression of WM1366 melanoma xenografts. A) Photographs of representative vehicle and dinaciclib-treated WM1366 tumors taken after day 14 of treatment. After tumor establishment, mice were dosed twice daily with either vehicle (20% HPBCD) or dinaciclib (5 mg/kg in 20% HPBCD) intraperitoneally for 14 days. B) Growth curves of vehicle or dinaciclib-treated mice. Tumor volumes were measured twice a week and were normalized to the start volumes. Dinaciclib led to tumor regression after 14 days of treatment (p = .0046). C) Dinaciclib treatment led to the downregulation of pRBser807/811, upregulation of p53, and inhibition of Bcl-2. Tumor samples were extracted from SCID mice after 14 days of treatment with dinaciclib or vehicle and were analyzed via western blot. Blots were stripped once and equal protein loading was confirmed by probing the blots for actin expression. doi:10.1371/journal.pone.0059588.g004

Dinaciclib Down-regulates Retinoblastoma Phosphorylation and the Expression of Anti-apoptotic Proteins in vitro

Next, we confirmed the biochemical data from our in vivo study in a series of in vitro experiments. Treatment of the BRAF V600E-mutated melanoma cell line 1205Lu with dinaciclib (30 nM, 0–48 hrs) led to a decrease in the extent of RB phosphorylation at Ser 807/811 (Figure 5). At the same time, we noted that the level of p53 expression markedly increased. Interestingly, the increase in p53 occurred more rapidly than the observed decrease in RB
Melanoma Cells
increase in PARP cleavage (Figure S1).

The pro-apoptotic effect of dinaciclib could be observed by an
phosphorylation at Ser 807/811 decreased and p53 increased.
when the WM35 cell line was treated with dinaciclib 30 nM RB
apoptotic proteins Mcl-1, XIAP, and Bcl-2 (Figure 5). Similarly,
induction of caspase-3 cleavage and a decrease in the anti-
survival molecules Bcl-2, XIAP, and Mcl-1. The membrane was probed
for actin expression to ensure equal protein loading.
doi:10.1371/journal.pone.0059588.g005

Discussion

Overcoming intrinsic and acquired drug resistance of melano-
ma is a major challenge. Melanomas are relatively unique in
cancer biology in being intrinsically resistant to nearly every
chemo-therapeutic agent tried thus far [11]. Novel therapies
targeting the BRAF oncogene, which is mutated in almost 50% of
all melanomas, have demonstrated clinical benefit in melanoma
patients. However, repeated experience has shown that melanomas
acquired resistance even to new agents selectively targeting
BRAF [4]. In this study, we characterize an inhibitor of CDKs
with remarkable pro-apoptotic activity against human melanoma
cells grown under 2D adherent culture conditions, 3D organotypic
culture conditions, and in mouse xenografts.

There is currently much interest in the idea of “personalized
cancer therapy”, a paradigm whereby patients are selected based
on the genetic/mutational profiles of their tumors and given
targeted therapies directed against the driving oncogenic muta-
tions. This approach has shown success in melanoma, where
carefully selected patients harboring BRAFV600E activating
mutations are receiving inhibitors of the MAPK pathway, which
is constitutively active due to this mutation [5,32]. This approach
is also self-evident when considering CDK’s as a potential
melanoma-specific therapeutic target. Previous work has shown
that melanoma sub-groups exist with either high or low expression
levels of CDK2, with the low CDK2 expressing cell lines posited
to be the optimal group for receiving CDK2 inhibitor therapy [24].
An initial screen of our panel of melanoma cell lines identified a
group of melanoma cell lines with high CDK2 expression and a
group with low CDK2 expression. At the RNA level, there was
good positive correlation between levels of CDK2 and the
expression of CDK2, whereas there was some variability within
the NRAS mutated melanoma cell lines. Interestingly, there was also some
stratification between CDK2 expression level and BRAF/NRAS
mutational status. We also found that all of the NRAS mutated
melanoma lines evaluated (or included in our panel) had low
expression of CDK2, whereas there was some variability within
the BRAF-V600E mutated group, with some cell lines harboring
high expression of CDK2 and some with low expression. These
results are consistent with CDK2 being a downstream target of the
MITF transcription factor in melanoma [24], as previous work has
shown that all of the cell lines in the NCI-60 cell line panel with
MITF amplification also harbored a BRAF-V600E mutation [33].
Although we saw agreement between CDK2 and MITF levels at the
RNA level, there was some variability in the levels of MITF
protein expression that did not always match with CDK2 protein
levels. It is likely that this lack of clear correlation is a consequence
of the complex system of post-translational modification and
proteasomal targeting seen with MITF.

The observed anti-melanoma effects most likely result from cdk
inhibition, though secondary effects of the compound cannot be
ruled out.
Figure 6. shRNA knockdown of p53 expression reverses dinaciclib-induced apoptosis. A) Knockdown of p53 levels using a lentiviral shRNA construct. WM35 melanoma cells were infected with a lentivirus encoding for shRNA against p53 and were selected by flow cytometric sorting for GFP (designated WM35 shp53). Western blot shows knockdown of p53 protein. Actin shows equal protein loading. B) WM35 cells expressing p53 shRNA show diminished cell accumulation in the sub-G1 phase of the cell cycle following dinaciclib treatment. Cells were treated with 30 nM of dinaciclib for either 12 hours or 24 hours, before being fixed and stained for DNA content with propidium iodide. C) Apoptosis in a wild-type p53 melanoma cell line is dependent upon p53. WM35 and WM35 shp53 cells were treated with 30 nM dinaciclib for 48 hrs and were assessed for apoptosis via Annexin-V staining. WM35 shp53 cells exhibited a dramatic reduction of apoptosis when compared to WM35. D) The knockdown of p53 led to decreased pRB (ser805/811) and a decrease in cleaved PARP in cells treated with dinaciclib. WM35 and WM35 shp53 cells were treated with 30 nM of dinaciclib for 8, 16, 24, and 48 hrs, after which protein were assessed for the levels of p53, pRBser805/811, PARP, and Mcl-1. Actin was used as loading control.

doi:10.1371/journal.pone.0059588.g006
Treatment of a panel of melanoma cell line with dinaciclib led to a very potent inhibition of cell growth and induction of apoptosis. There was no correlation between CDK2 expression levels and sensitivity of the cell lines to dinaciclib, suggesting that dinaciclib is not functioning exclusively as a CDK2 inhibitor. As it has been previously shown that the BRAF V600E mutation conveys sensitivity of melanoma cells to BRAF [34,35,36] and MEK [37] inhibitors and the phenothiazine compounds [38], we next addressed whether the presence of a BRAF or NRAS mutation conferred sensitivity to dinaciclib. We observed that there was no apparent correlation between dinaciclib response and BRAF/ NRAS mutational status, leading us to conclude that dinaciclib had broad-spectrum anti-melanoma activity and was not conclusively mutation specific.

A number of previous studies have shown that intracellular signaling and drug resistance are modified by the tumor microenvironment. In particular, our group has previously shown that melanoma cells derived from metastases become almost completely resistant to certain inhibitors when grown under 3D organotypic cell culture conditions [39]. We found that both the BRAF-mutated 1205Lu and NRAS-mutated WM1366 melanoma cell lines retain their sensitivity to dinaciclib when grown as 3D collagen-implanted spheroids, suggesting that modulating the tumor microenvironmental conditions does not increase resistance to this compound. Other melanoma targeted therapies, such as the MEK inhibitors, are associated with reversible cytostatic effects when grown under 3D organotypic cell culture and in vivo conditions [39]. Here we show that a 14-day dinaciclib treatment of established WM1366 melanoma tumors in vivo led to a marked inhibition of tumor growth and some degree of regression, suggesting that dinaciclib was having significant cytostatic effects beyond induction of G2/M phase cell cycle arrest. Biochemically, dinaciclib treatment led to reduced expression of the anti-apoptotic proteins Bcl-2, Mcl-1 and XIAP. Downregulation of these anti-apoptotic proteins is a common feature of other CDK inhibitors, particularly those that have selectivity for CDK9 [15]. Thus it has been shown that both UCN-01 and flavopiridol decrease the expression of Mcl-1, XIAP, BAG-1, and Bcl-2 in B-cell chronic lymphocytic leukemia cells [15,40]. The downregulation of pro-apoptotic gene expression following CDK9 inhibition is likely to be one of the major pro-apoptotic mechanisms of these compounds. In particular, the ability of dinaciclib to regulate these anti-apoptotic proteins is likely to be of great utility in melanoma where overexpression of XIAP [41], Bcl-2 [42] and Mcl-1 [43] is commonplace and can contribute to melanoma chemoresistance.

Dinaciclib treatment also led to the induction of p33 expression under both in vitro and in vivo conditions. The role of p33 in melanoma and its potential role in therapy remains somewhat unclear since melanomas generally harbor very low rates of p33 mutations and are generally poor at undergoing p33-dependent apoptosis. Previous work from our group has shown that melanomas can tolerate high levels of p33 expression and do not undergo apoptosis [13]. The lack of p33-dependent apoptosis under these conditions is likely a consequence of high expression levels of the E3-ubiquitin ligase MDM2 (or HDM2) [44], which holds the transcriptional activity of p33 in check by targeting it to the proteasome. More than 50% of primary invasive and metastatic melanomas overexpress HDM2 which contributes to the lack of p33 activity in melanoma [44]. More recently, it has been shown that MDM4 is upregulated in 65% of melanomas promoting tumor survival by counteracting the effects of p33 [45]. However, under certain conditions, p33 can become pharmacologically activated in melanoma cells. We and others have previously demonstrated that the pharmacological activation of p33 via either GSK3β inhibition or Nutlin-3 induced high levels of apoptosis in melanoma cells [13,46]. Activation of p33 also seems to be a critical determinant of dinaciclib-induced apoptosis, with selective knockdown of p33 expression leading to a marked inhibition of dinaciclib-induced apoptosis. Interestingly, knockdown of p33 expression was still associated with the dinaciclib-induced reduction in the expression of Mcl-1. This demonstrates either that loss of Mcl-1 was not critical to the pro-apoptotic activity of dinaciclib or that the reduced expression of Mcl-1 still requires functional p33 to induce apoptosis.

Dinaciclib has shown preclinical in vitro and in vivo activity in pancreatic, osteosarcoma and melanoma models [47,48,49]. Dinaciclib showed moderate activity in a phase 2 trial of melanoma with acceptable toxicity [50]. Our work mechanistically supports the anti-melanoma activity of dinaciclib and further demonstrates its potential as a novel therapy for this disease. In addition, the ability of dinaciclib to pharmacologically activate p33 suggests that dinaciclib could be an ideal candidate for combinations with cytotoxic chemotherapies, as a possible mechanism to overcome chemoresistance. This idea fits well with previously published studies showing that flavopiridol potentiates the induction of apoptosis seen following treatment with mitomycin C, paclitaxel, SN-38, and topoisomerase I inhibitors in gastric and breast cancer cell lines [51]. In these studies, p53 function was critical for the flavopiridol’s ability to potentiate chemotherapy-induced apoptosis, with the extent of apoptosis induced being 5-fold greater in p53 (+/+) HCT116 cells compared to that seen in p53 (−/−) HCT166 cells [51]. Since most melanomas lack p33 mutations [3], it can be reasoned that dinaciclib should have good pro-apoptotic activity across the spectrum of melanoma patients when combined with agents such as those targeted against BRAF/ MEK signaling. Data have previously shown that melanoma cells do not undergo apoptosis following MEK inhibitor treatment as a result of constitutively high Mcl-1 expression levels [43]. A compound such as dinaciclib, which downregulates Mcl-1 expression, could be an ideal combination candidate in future preclinical and clinical studies.

Supporting Information

Figure S1 Western Blot data of WM35 cells treated with 30 nM of dinaciclib for increasing periods of time (0–48 hrs). Along with a decrease in pRbser807/811, dinaciclib induced a marked upregulation of p33, and increase in cleaved PARP. Actin was used to ensure equal protein loading. (TIF)

Figure S2 Knockdown of p33 levels using a lentiviral shRNA construct. 1205Lu melanoma cells were infected with a lentivirus encoding for shRNA against p33 and were selected by flow cytometric sorting for GFP (designated 1205Lu shp33). 1205Lu and 1205Lu shp53 cells were treated with 30 nM of dinaciclib for 8, 16, 24, and 48 hrs, Western blot shows knockdown of p33 protein. 1205Lu cells treated with dinaciclib showed decrease in pRb (ser807/811) and increase in cleaved PARP as an indicator of apoptosis. In The 1205Lu shp53 cells dinaciclib treatment did not induce cleavage of PARP and only a slight decrease in pRb levels. Actin was used as loading control. (TIF)

Table S1 Quantification of spheroid invasion into surrounding collagen matrix. Preformed melanoma spheroids that harbored either the BRAF V600E mutation (1205Lu) or NRAS mutation (WM1366) were embedded into collagen and overlaid with medium. Spheroids were then treated with either
References

1. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Research 62: 6997–7000.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949–954.
3. Hodis E, Watson Ian R, Kryukov Gregory V, Arold Stefan T, Irimie M, et al. (2012) A Landscape of Driver Mutations in Melanoma. Cancer Cell 15: 4215–4224.
4. Nikolova VA, Stratigos AJ, Halbert KT, Tsao H (2012) Melanoma. New Insights and New Therapies. The Journal of investigative dermatology.
5. Sosman JA, Kin KB, Schuchter L, Gonzalez R, Pavlick AC, et al. (2012) Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib. New England Journal of Medicine 366: 707–716.
6. Palancade B, Bensaude O (2003) Investigating RNA polymerase II carboxy-terminal domain (CTD) function. Genes Dev 17: 1401–1415.
7. Meinhart A, Kaminski T, Hopperg S, Baumli S, Gramer P (2005) A structural perspective of CTD function. Genes Dev 19: 1401–1415.
8. Do J, Wisland HR, Horstmann MA, Ramaoshwani S, Ross K, et al. (2004) CRITICAL role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MIFTF. Cancer Cell 6: 565–576.
9. Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E, et al. (2005) Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol 166: 1541–1554.

Acknowledgments

We thank the Microscopy Facility managed by Jeffrey S. Faust, and the Animal Facility

Author Contributions

Conceived and designed the experiments: BMD JV TTKN ML MX KTF KLNS MH. Performed the experiments: BMD JV TTKN ML MX JK KLN. Analyzed the data: BMD JV TTKN ML CK AV KLNS KMSM. Contributed reagents/materials/analysis tools: KTF KLNS MH. Wrote the paper: BMD JV CK AV KLNS KTF MH.

Brunner Melck TR, Bernard R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 500–503.
27. Hock KS, Schlegel NC, Bradford P, Sucker A, Ugerel S, et al. (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BR signature. Pigment Cell Res 19: 292–296.
28. Tsavachidou D, Colaman ML, Athanasiadis G, Li S, Lucht JD, et al. (2004) SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E/R-loop allele. Mol Cell 16: 292–297.
29. Spritle C, Ward MR, Nathanson KL, Gimpoty PA, Rapport E, et al. (2007) Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 9: 469–471.
30. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, et al. (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cells derived from melanoma metastases. Mol Cancer Ther 5: 1136–1144.
31. Jordan JJ, Inga A, Conway K, Edmiston S, Carey LA, et al. (2010) Altered-Function p53 Mutations Identified in Breast Cancers Can Have Subtle Effects on Transactivation. Molecular Cancer Research 8: 701–716.
32. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, et al. (2012) Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine 367: 107–114.
33. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117–122.
34. Flaherty KT, Puzanov I, Kin KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809–819.
35. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. (2010) Clinical efficacy of a BRAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596–599.
36. Tsai J, Lee JT, Wang W, Zhang J, Cho H, et al. (2008) Discovery of a selective inhibitor of oncopgenic B-Raf kinase with potent antimalanoma activity. Proceedings of the National Academy of Sciences 105: 3041–3046.
37. Sollit DB, Garraway LA, Casta CA, Savai A, Getz G, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358–362.
38. Redlich OS, Reimers M, Durink S, Blower P, Furlaud AP, et al. (2006) In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 B-Raf allele. Mol Cancer Ther 5: 1136–1146.
39. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, et al. (2008) The mitogen-activated protein kinase inhibitor Dinaciclib inhibits pancreatic cell cycle and may contribute to proliferation. BMC cancer 11: 203.
40. Jordan JJ, Inga A, Conway K, Edmiston S, Carey LA, et al. (2010) Altered-Function p53 Mutations Identified in Breast Cancers Can Have Subtle Effects on Transactivation. Molecular Cancer Research 8: 701–716.
41. Emanuel PO, Phelps RG, Mudgil A, Shafir M, Burstein DE (2008) Multiple signaling pathways must be targeted to overcome drug resistance in cells derived from melanoma metastases. Mol Cancer Ther 5: 1136–1144.
cancer growth and progression in murine xenograft models. Cancer Biology & Therapy 12: 598–609.

48. Fu W, Ma L, Chu B, Wang X, Bui MM, et al. (2011) The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinaciclib) Induces the Apoptosis of Osteosarcoma Cells. Molecular Cancer Therapeutics 10: 1018–1027.

49. Abdullah C, Wang X, Becker D (2011) Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. Cell Cycle 10: 977–988.

50. Lao CD, Moon J, Fruehauf JP, Flaherty LE, Bury MJ, et al. (2012) SWOG S0126: A phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma. Journal of Clinical Oncology 30.

51. Ambrosini G, Seelman SL, Qin LX, Schwartz GK (2008) The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res 68: 2312–2320.